Skip to main content
Back
NUTX logo

Nutex Health, Inc.

Data quality: 100%
NUTX
NASDAQ Healthcare Medical - Healthcare Information Services
$99.49
▲ $4.51 (4.75%)
Mkt Cap: 592.40M
Day Range
$93.02 $100.73
52-Week Range
$45.88 $193.07
Volume
175,497
50D / 200D Avg
$122.92 / $118.80
Prev Close
$94.98

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (627 peers)

Metric Stock Sector Median
P/E 8.4 0.3
P/B 1.8 2.9
ROE % 29.8 3.7
Net Margin % 8.1 3.8
Rev Growth 5Y % 27.5 10.0
D/E 1.1 0.2

Analyst Price Target

Hold
$205.00 +106.1%
Forward P/E
6.2
Forward EPS
$15.41
EPS Growth (est.)
+0.0%
Est. Revenue
910 M

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2027 $17.56
$16.79 – $18.62
 950 M 1
FY2026 $15.41
$14.74 – $16.35
 910 M 1

Key Takeaways

Revenue grew 27.47% annually over 5 years — strong growth
Earnings grew 35.67% over the past year
ROE of 29.76% indicates high profitability
Generating 245.60M in free cash flow
P/E of 8.37 — trading at a low valuation
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 54.89%

Growth

Revenue Growth (5Y)
27.47%
Revenue (1Y)82.36%
Earnings (1Y)35.67%
FCF Growth (3Y)N/A

Quality

Return on Equity
29.76%
ROIC30.36%
Net Margin8.09%
Op. Margin31.49%

Safety

Debt / Equity
1.07
Current Ratio3.41
Interest Coverage12.40

Valuation

P/E Ratio
8.37
P/B Ratio1.80
EV/EBITDA2.75
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 82.36% Revenue Growth (3Y) 88.00%
Earnings Growth (1Y) 35.67% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 27.47% Earnings Growth (5Y) -14.52%
Profitability
Revenue (TTM) 875.26M Net Income (TTM) 70.79M
ROE 29.76% ROA 7.71%
Gross Margin 50.76% Operating Margin 31.49%
Net Margin 8.09% Free Cash Flow (TTM) 245.60M
ROIC 30.36% FCF Growth (3Y) N/A
Safety
Debt / Equity 1.07 Current Ratio 3.41
Interest Coverage 12.40 Dividend Yield 0.00%
Valuation
P/E Ratio 8.37 P/B Ratio 1.80
P/S Ratio 0.68 PEG Ratio 1.77
EV/EBITDA 2.75 Dividend Yield 0.00%
Market Cap 592.40M Enterprise Value 758.21M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 875.26M 479.95M 247.65M 219.29M 331.53M
Net Income 70.79M 52.18M -45.79M -424.78M 132.59M
EPS (Diluted) 10.48 9.71 -10.39 -100.36 33.55
Gross Profit 444.28M 196.26M 34.77M 15.42M 179.28M
Operating Income 275.63M 130.62M -31.77M -406.60M 170.26M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 918.53M 655.32M 398.25M 431.75M 394.65M
Total Liabilities 495.09M 453.43M 319.14M 311.42M 203.07M
Shareholders' Equity 329.45M 146.34M 61.45M 95.86M 114.65M
Total Debt 351.39M 340.30M 275.76M 267.20M 178.55M
Cash & Equivalents 185.57M 43.58M 22.00M 34.26M 36.12M
Current Assets 538.81M 292.48M 90.85M 97.97M 154.02M
Current Liabilities 157.91M 140.87M 58.31M 54.86M 37.69M

Strategy Scores

This stock passed the criteria for 5 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#89 of 1052
72
Growth Price/Sales Ratio Focus (Ken Fisher)
#19 of 618
88
Custom Contrarian Investing (David Dreman)
#165 of 670
49
Growth Growth Investing (Philip Fisher)
#43 of 157
72
Custom Full Throttle
#26 of 146
62

Recent Activity

Entered Cash Flow Compounder
Mar 24, 2026
Entered Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Entered Contrarian Investing (David Dreman)
Mar 24, 2026
Entered Growth Investing (Philip Fisher)
Mar 24, 2026
Entered Full Throttle
Mar 24, 2026